Key Stats for Pfizer Stock
- Price change for Pfizer stock: 1%
- $PFE Share Price as of May. 5: $26
- 52-Week High: $29
- $PFE Stock Price Target: $29
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Pfizer (PFE) stock climbed after the company beat Wall Street expectations on both revenue and earnings for Q1 2026.
- Revenue came in at $14.45 billion, well above the $13.79 billion analysts had forecast.
- Adjusted EPS hit $0.75, topping the $0.72 estimate.
- These aren’t massive beats, but in a market where investors have been nervous about Pfizer stock, the results provided real reassurance.
A few products stood out.
- Eliquis brought in $2.17 billion, up 13% year over year.
- Cancer drug Padcev grew 39%.
- Even the RSV (respiratory syncytial virus) vaccine surprised to the upside.
- Together, newly launched and acquired products grew 22% in the quarter, reaching $3.1 billion.
The one soft spot was Covid.
- Comirnaty and Paxlovid both missed estimates, falling sharply from a year ago.
- But the market had largely priced this in, and the strength elsewhere more than made up for it.
The bigger news may be longer term.
- Pfizer recently settled patent disputes around its heart drug Vyndamax, extending U.S. exclusivity to mid-2031.
- CEO Albert Bourla called it a development that could “change the growth profile of the company significantly post-2028.”
- Management now expects high-single-digit annual revenue growth for five years post-2028.
See analysts’ growth forecasts and price targets for Pfizer stock (It’s free) >>>
What the Market Is Telling Us About Pfizer Stock
Pfizer stock has had a rough stretch, just 5% up this year heading into earnings.
Today’s move suggests investors are willing to give the company credit for steadier execution. The Covid headwinds are well known.
What matters now is whether the newer drug lineup and pipeline can carry the business through the next few years of patent losses.
Guidance was reaffirmed at $59.5 to $62.5 billion in full-year revenue and $2.80 to $3.00 in adjusted EPS.
It’s not a blowout outlook, but holding the line after a shaky start to the year counts for something.
Pfizer stock remains a show-me story, but today was a step in the right direction.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Pfizer Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
